# EDGAR Filing Document

**Accession Number:** 0001755970
**File Stem:** 0001214659-26-002041
**Filing Date:** 2026-2
**Character Count:** 7835
**Document Hash:** b5fa3cd61fc48ace77203ecc6d44db31
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-26-002041.hdr.sgml**: 20260217

**ACCESSION NUMBER**: 0001214659-26-002041

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260212

**FILED AS OF DATE**: 20260217

**DATE AS OF CHANGE**: 20260217

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Finn Patrick John
- **CENTRAL INDEX KEY:** 0001755970

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38720
- **FILM NUMBER:** 26641993

**MAIL ADDRESS:**
- **STREET 1:** C/O TWIST BIOSCIENCE CORPORATION
- **STREET 2:** 455 MISSION BAY BOULEVARD SOUTH
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Twist Bioscience Corp
- **CENTRAL INDEX KEY:** 0001581280
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 462058888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**BUSINESS ADDRESS:**
- **STREET 1:** 681 GATEWAY BLVD.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 800-719-0671

**MAIL ADDRESS:**
- **STREET 1:** 681 GATEWAY BLVD.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Finn Patrick John<br><sub>(Last) (First) (Middle)</sub><br>C/O TWIST BIOSCIENCE CORPORATION<br>681 GATEWAY BLVD.<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-12 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President and COO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Twist Bioscience Corp [ TWST ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-12 |  | M |  | 1000<sup>(1)</sup> | A | $23.33 | 308788 | D |  |
| Common Stock | 2026-02-12 |  | M |  | 1500<sup>(1)</sup> | A | $26.66 | 310288 | D |  |
| Common Stock | 2026-02-12 |  | S |  | 3500<sup>(2)</sup> | D | $50.225 | 306788 | D |  |
| Common Stock | 2026-02-13 |  | M |  | 500<sup>(1)</sup> | A | $23.33 | 307288 | D |  |
| Common Stock | 2026-02-13 |  | M |  | 712<sup>(1)</sup> | A | $26.66 | 308000 | D |  |
| Common Stock | 2026-02-13 |  | S |  | 1750<sup>(2)</sup> | D | $50.041 | 306250 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $26.66 | 2026-02-12 |  | M<sup>(1)</sup> |  |  | 1500 | <sup>(3)</sup> | 2028-11-18 | Common Stock | 1500 | $0 | 33012 | D |  |
| Stock Option (right to buy) | $23.33 | 2026-02-12 |  | M<sup>(1)</sup> |  |  | 1000 | <sup>(4)</sup> | 2029-10-23 | Common Stock | 1000 | $0 | 18705 | D |  |
| Stock Option (right to buy) | $26.66 | 2026-02-13 |  | M<sup>(1)</sup> |  |  | 712 | <sup>(3)</sup> | 2028-11-18 | Common Stock | 712 | $0 | 32300 | D |  |
| Stock Option (right to buy) | $23.33 | 2026-02-13 |  | M<sup>(1)</sup> |  |  | 500 | <sup>(4)</sup> | 2029-10-23 | Common Stock | 500 | $0 | 18052 | D |  |

---

### Footnotes:

(1) The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025.

(2) Represents the weighted average sales price per share. The shares sold at prices ranging from $50.00 to $50.51 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

(3) The option is immediately exercisable. 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

(4) The option is immediately exercisable. 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date.

**Signature:** /s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn  
**Date:** 2026-02-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**